Table 2 Association of androgen receptor expression with clinicopathologic features of endometrial carcinoma
| Â | n (%) | P value | ||||
|---|---|---|---|---|---|---|
Negative (n = 71) | Low (n = 7) | Moderate (n = 10) | High (n = 1) | Total (n = 89) | ||
Menopausal status | ||||||
 Pre menopausal | 14 (19.7) | 2 (28.6) | 1 (10) | 0 (0) | 17 (19.1) | 0.743 |
 Post menopausal | 57 (80.3) | 5 (71.4) | 9 (90) | 1 (100) | 72 (80.9) | |
Histological type | ||||||
 Endometrioid | 62 (87.3) | 5 (71.4) | 10 (100) | 0 (0) | 77 (86.5) | 0.117 |
 Serous | 4 (5.6) | 2 (28.6) | 0 (0) | 1 (100) | 7 (7.9) | |
 Clear cell | 1 (1.4) | 0 (0) | 0 (0) | 0 (0) | 1 (1.1) | |
 Carcinosarcoma | 4 (5.6) | 0 (0) | 0 (0) | 0 (0) | 4 (4.5) | |
Grade | ||||||
 Grade I | 28 (39.4) | 3 (42.9) | 4 (40) | 0 (0) | 35 (39.3) | 0.293 |
 Grade II | 30 (42.3) | 2 (28.6) | 6 (60) | 0 (0) | 38 (42.7) | |
 Grade III | 13 (18.3) | 2 (28.6) | 0 (0) | 1 (100) | 16 (18) | |
Myometrial invasion | ||||||
 Limited to endometrium | 4 (5.6) | 0 (0) | 2 (20) | 0 (0) | 6 (6.7) | 0.518 |
 < 1/2 of myometrium | 26 (36.6) | 3 (42.9) | 2 (20) | 0 (0) | 31 (34.8) | |
 > 1/2 of myometrium | 41 (57.7) | 4 (57.1) | 6 (60) | 1 (100) | 52 (58.4) | |
Cervical invasion | ||||||
 Present | 17 (23.9) | 3 (42.9) | 3 (30) | 0 (0) | 23 (25.8) | 0.581 |
 Absent | 54 (76.1) | 4 (57.1) | 7 (70) | 1 (100) | 66 (74.2) | |
Nodal status | ||||||
 N0 | 67 (94.4) | 6 (85.7) | 10 (100) | 1 (100) | 84 (94.4) | 0.499 |
 N1 | 3 (4.2) | 1 (14.3) | 0 (0) | 0 (0) | 4 (4.5) | |
 N2 | 1 (1.4) | 0 (0) | 0 (0) | 0 (0) | 1 (1.1) | |
Lymphovascular invasion | ||||||
 Present | 5 (7) | 1 (14.3) | 0 (0) | 0 (0) | 6 (6.7) | 0.529 |
 Absent | 66 (93) | 6 (85.7) | 10 (100) | 1 (100) | 83 (93.3) | |
T stage | ||||||
 T1 | 51 (71.8) | 4 (57.1) | 6 (60) | 1 (100) | 62 (69.7) | 0.607 |
 T2 | 10 (14.1) | 3 (42.9) | 3 (30) | 0 (0) | 16 (18) | |
 T3 | 7 (9.9) | 0 (0) | 1 (10) | 0 (0) | 8 (9) | |
 T4 | 3 (4.2) | 0 (0) | 0 (0) | 0 (0) | 3 (3.4) | |
FIGO stage | ||||||
 Stage IA | 28 (39.4) | 2 (28.6) | 4 (40) | 0 (0) | 34 (38.2) | 0.853 |
 Stage IB | 22 (31) | 2 (28.6) | 2 (20) | 1 (100) | 27 (30.2) | |
 Stage II | 11 (15.5) | 3 (42.9) | 3 (30) | 0 (0) | 17 (19.1) | |
 Stage IIIA | 6 (8.5) | 0 (0) | 1 (10) | 0 (0) | 7 (7.9) | |
 Stage IIIB | 1 (1.4) | 0 (0) | 0 (0) | 0 (0) | 1 (1.1) | |
 Stage IV | 3 (4.2) | 0 (0) | 0 (0) | 0 (0) | 3 (3.4) | |